Sichuan Hebang Biotechnology Corporation Limited
603077.SS · SHH
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 25.08 | 0.41 | -2.66 | 0.03 |
| FCF Yield | -0.21% | 0.45% | -2.71% | 0.21% |
| EV / EBITDA | 126.28 | 54.69 | 53.71 | -156.38 |
| Quality | ||||
| ROIC | 0.15% | 0.12% | 0.03% | -0.99% |
| Gross Margin | 14.73% | 8.19% | 10.70% | -11.07% |
| Cash Conversion Ratio | 4.00 | – | – | – |
| Growth | ||||
| Revenue 3-Year CAGR | -5.16% | -7.57% | -12.49% | -13.13% |
| Free Cash Flow Growth | -157.77% | 115.87% | -1,236.26% | 113.83% |
| Safety | ||||
| Net Debt / EBITDA | 14.26 | 4.99 | 4.42 | -2.85 |
| Interest Coverage | 4.69 | 1.18 | 0.76 | -49.23 |
| Efficiency | ||||
| Inventory Turnover | 0.42 | 0.48 | 0.33 | 0.42 |
| Cash Conversion Cycle | 243.03 | 208.00 | 281.53 | 221.52 |